Success Stories: In Record Time of 3 Days, NAILG Obtains EB1-A Approval for a Senior Scientist in Cancer Immunotherapy from India, Thanks to the Premium Processing Upgrade and Our Excellent Case Preparation Process
Client’s Testimonial:
“Thank you for helping me to get the I-140 approval.”
On March 24th, 2022, we received another EB-1A (Alien of Extraordinary Ability) approval for a Senior Scientist in the Field of Cancer Immunotherapy (Approval Notice).
General Field: Cancer Immunotherapy
Position at the Time of Case Filing: Senior Scientist
Country of Origin: India
State of Residence at the Time of Filing: Pennsylvania
Approval Notice Date: March 24th, 2022
Processing Time: 3 days (Premium Processing Requested)
Case Summary:
“Cancer, in general, has a severe impact on not only patients and their families but also economic resources and opportunities in the US due to morbidity, financial loss, reduced quality of life, and premature death. As a foremost expert in cancer immunotherapy, [the client] specializes in the research and development of novel therapies for all kinds of cancers, making her contributions a boon to the American healthcare sector. I lend her my full support in her continued endeavors.”
This statement supports the work of one of our clients from India. She had come to NAILG seeking help with her EB1-A (Alien of Extraordinary Ability) petition. At the time of filing, she held a Ph.D. in immunology and was employed as a senior scientist in cancer immunotherapy. It was evident to our team that she was an extraordinary individual and one of the few leading cells therapy experts in the area. Additionally, she held a consistent and notable record of success and influence in this area of study.
Our client was especially well-known for her work on developing personalized chimeric antigen receptor T (CAR T) cell-based immunotherapies for patients diagnosed with mutations in epidermal growth factor receptors in glioblastoma multiforme. Given that she had spent years investigating these issues, she had come to be regarded as an authority in the field. The field had also recognized her authority by inviting her to review and evaluate the work of her peers no fewer than 2 times.
At the same time, her work has resulted in 9 peer-reviewed scientific articles, 1 patent, and 2 patent applications. And these publications have been cited by researchers in at least 49 countries some 554 times according to Google Scholar, thereby demonstrating that these publications are widely recognized and relied upon in the field of cancer immunotherapy.
This was the reason that her work in the area found many supporters such as the 4 experts who wrote recommendations in our client’s favor. These letters were of immense help in the adjudication process since the USCIS demands clear proof of extraordinary ability from petitioners in this category. One of these experts had the following to say about the continuation of her work in the United States:
“To curb the devastating effects that cancer has on patients and the economy, the discovery of novel therapeutics for the disease is necessary. [The client] has dedicated her career to investigating this topic as it relates to glioblastoma, Acute Myelogenous Leukemia, pancreatic cancer, and several other forms of the disease. For progress in this area to continue at its present pace, she must be allowed to continue her research unabated.”
Finally, when we received her EB1-A approval in the record time of just 3 days, we could not contain our happiness. We are also grateful for her continuing trust in our firm, and for retaining us to file her I-485 application and successfully receiving her green card 4 months after we filed her case. We cordially thank her for her support and wish her the best in her future endeavors.